Jan Brabender
Overview
Explore the profile of Jan Brabender including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grimminger P, Maus M, Bergenthal J, Wandhofer C, Fetzner U, Herbold T, et al.
Anticancer Res
. 2015 Mar;
35(3):1297-302.
PMID: 25750278
Background/aim: The prognostic value of TS (thymidylate synthase) and DPD (dihydropyrimidine dehydrogenase) RNA expression in the blood of patients with esophageal cancer is not known. The aim of the present...
2.
Grimminger P, Maus M, Schneider P, Metzger R, Holscher A, Sugita H, et al.
Lung Cancer
. 2012 Aug;
78(1):87-91.
PMID: 22884253
Introduction: The aim of this study was to investigate the relevance of mRNA expression and DNA methylation of GST-PI in tumor and non-tumor lung tissue from NSCLC patients in terms...
3.
Reuter H, Seuthe K, Korkmaz Y, Gronke S, Hoyer D, Rottlaender D, et al.
Int J Cardiol
. 2012 May;
167(4):1476-85.
PMID: 22560942
Aims/hypothesis: Pathological cardiac hypertrophy is an early phenotype in both types 1 and 2 diabetes. The primary stimulus for hypertrophic growth in diabetes is yet unknown and may involve neurohumoral...
4.
Brabender J, Metzger R, Vallbohmer D, Ling F, Neiss S, Bollschweiler E, et al.
Surgery
. 2011 Oct;
151(2):306-12.
PMID: 21982526
Background: Thymidylate synthetase (TS) and dihydropyrimidine dehydrogenase (DPD) RNA expression in peripheral blood was examined as a noninvasive molecular predictor of response to neoadjuvant radiochemotherapy in patients with locally advanced...
5.
Metzger R, Warnecke-Eberz U, Alakus H, Kutting F, Brabender J, Vallbohmer D, et al.
J Gastrointest Surg
. 2011 Sep;
16(1):26-34.
PMID: 21956434
Introduction: Neoadjuvant radiochemotherapy (RT/CTx) regimens were primarily designed for treatment of squamous cell carcinoma of the esophagus. Own preliminary results demonstrate that also patients with locally advanced adenocarcinoma of the...
6.
Vallbohmer D, Brabender J, Grimminger P, Schroder W, Holscher A
Expert Rev Anticancer Ther
. 2011 Sep;
11(9):1449-55.
PMID: 21929318
Despite improvements in preoperative staging, surgical techniques and postoperative care, the 5-year survival rate of patients with locally advanced esophageal cancer remains only approximately 15-40%. Therefore, multimodality treatment options have...
7.
Drebber U, Lay M, Wedemeyer I, Vallbohmer D, Bollschweiler E, Brabender J, et al.
Int J Oncol
. 2011 May;
39(2):409-15.
PMID: 21567082
microRNAs (miRNAs) are small non-coding RNAs with important post-transcriptional regulatory functions. miRNA-21 (miR-21) is upregulated and miR-143 and miR-145 are downregulated in colorectal carcinoma. The aim of our study was...
8.
Drebber U, Madeja M, Odenthal M, Wedemeyer I, Monig S, Brabender J, et al.
Int J Colorectal Dis
. 2011 May;
26(9):1127-34.
PMID: 21538055
Background: Neoadjuvant treatment strategies have been developed to improve survival of patients with advanced rectal cancer. Since mainly patients with major histopathological response benefit from this therapy, predictive and prognostic...
9.
Schneider P, Vallbohmer D, Ploenes Y, Lurje G, Metzger R, Ling F, et al.
Int J Colorectal Dis
. 2011 Feb;
26(7):903-9.
PMID: 21340717
Background And Aims: We evaluated the outcome of primarily resected rectal cancer patients immediately after the implementation of total meserectal excision (TME) based on potential quality indicators. Patients And Methods:...
10.
Narumiya K, Metzger R, Bollschweiler E, Alakus H, Brabender J, Drebber U, et al.
Pharmacogenomics
. 2011 Feb;
12(2):205-14.
PMID: 21332314
Aims: Neoadjuvant treatment strategies have been developed to improve the survival of patients with locally advanced esophageal cancer. Since patients with major histopathological response are the ones who mainly benefit...